Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Tyagi, F. Begnini, Vasanthanathan Poongavanam, B. Doak, J. Kihlberg (2020)
Drug Syntheses Beyond the Rule of 5.Chemistry
A. Savonenko, T. Melnikova, A. Hiatt, Tong Li, P. Worley, J. Troncoso, P. Wong, D. Price (2012)
Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug DevelopmentNeuropsychopharmacology, 37
Hao Zhu, Shiew-Mei Huang, R. Madabushi, D. Strauss, Yaning Wang, I. Zineh (2019)
Model‐Informed Drug Development: A Regulatory Perspective on ProgressClinical Pharmacology & Therapeutics, 106
Sukoff Rizzo SJ (2020)
Improving preclinical to clinical translation in Alzheimer's disease researchAlzheimers Dement (N Y), 6
(2020)
Open Science Delivers a Wealth of AD/ADRD Research Data to a Portal Near You
S. Surade, T. Blundell (2012)
Structural biology and drug discovery of difficult targets: the limits of ligandability.Chemistry & biology, 19 1
N. Patel (2020)
Methods to Optimize CNS Exposure of Drug Candidates.Bioorganic & medicinal chemistry letters
Savonenko AV (2012)
261Neuropsychopharmacology, 37
Cummings JL (2014)
37Alzheimers Res Ther, 6
C. Lipinski, F. Lombardo, B. Dominy, P. Feeney (1997)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 46
D. Selkoe (2011)
Alzheimer's disease.Cold Spring Harbor perspectives in biology, 3 7
B. Doak, Jie Zheng, D. Dobritzsch, J. Kihlberg (2016)
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets.Journal of medicinal chemistry, 59 6
A. Oblak, Zackary Cope, S. Quinney, Ravi Pandey, C. Biesdorf, A. Masters, K. Onos, Leslie Haynes, Kelly Keezer, Jill Meyer, Jonathan Peters, Scott Persohn, Amanda Bedwell, Kierra Eldridge, R. Speedy, G. Little, Sean‐Paul Williams, Brenda Noarbe, A. Obenaus, M. Sasner, Gareth Howell, G. Carter, Harriet Williams, B. Lamb, P. Territo, S. Rizzo (2022)
Prophylactic evaluation of verubecestat on disease‐ and symptom‐modifying effects in 5XFAD miceAlzheimer's & Dementia : Translational Research & Clinical Interventions, 8
D. Shineman, G. Basi, J. Bizon, C. Colton, B. Greenberg, B. Hollister, J. Lincecum, Gabrielle Leblanc, L. Lee, F. Luo, D. Morgan, Iva Morse, L. Refolo, D. Riddell, K. Scearce-Levie, P. Sweeney, J. Yrjänheikki, H. Fillit (2011)
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studiesAlzheimer's Research & Therapy, 3
Scheltens P (2021)
1577Lancet, 397
H. Kubinyi (1995)
Strategies and recent technologies in drug discovery.Die Pharmazie, 50 10
B. Doak, Björn Over, F. Giordanetto, J. Kihlberg (2014)
Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.Chemistry & biology, 21 9
N. Meanwell (2011)
Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.Chemical research in toxicology, 24 9
R. Odi, David Bibi, Travis Wager, M. Bialer (2020)
A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs—From phenobarbital to cenobamate and beyondEpilepsia, 61
J. Cummings, Travis Morstorf, K. Zhong (2014)
Alzheimer’s disease drug-development pipeline: few candidates, frequent failuresAlzheimer's Research & Therapy, 6
K. Onos, S. Quinney, David Jones, A. Masters, Ravi Pandey, Kelly Keezer, C. Biesdorf, I. Metzger, Jill Meyers, Johnathon Peters, Scott Persohn, B. McCarthy, Amanda Bedwell, Lucas Figueiredo, Zackary Cope, M. Sasner, G. Howell, Harriet Williams, A. Oblak, B. Lamb, G. Carter, S. Rizzo, P. Territo (2022)
Pharmacokinetic, pharmacodynamic, and transcriptomic analysis of chronic levetiracetam treatment in 5XFAD mice: A MODEL‐AD preclinical testing core studyAlzheimer's & Dementia : Translational Research & Clinical Interventions, 8
A. Oblak, S. Forner, P. Territo, M. Sasner, G. Carter, G. Howell, Stacey Sukoff‐Rizzo, B. Logsdon, L. Mangravite, A. Mortazavi, D. Baglietto-Vargas, K. Green, G. MacGregor, M. Wood, A. Tenner, F. LaFerla, B. Lamb (2017)
Model organism development and evaluation for late‐onset Alzheimer's disease: MODEL‐ADAlzheimer's & Dementia : Translational Research & Clinical Interventions, 6
E. McDade, I. Voytyuk, P. Aisen, R. Bateman, M. Carrillo, B. Strooper, C. Haass, E. Reiman, R. Sperling, P. Tariot, R. Yan, C. Masters, R. Vassar, S. Lichtenthaler (2021)
The case for low-level BACE1 inhibition for the prevention of Alzheimer diseaseNature Reviews Neurology, 17
Elizabeth Villar, D. Beglov, Spandan Chennamadhavuni, J. Porco, D. Kozakov, S. Vajda, A. Whitty (2014)
How Proteins Bind MacrocyclesNature chemical biology, 10
Travis Wager, Xinjun Hou, P. Verhoest, A. Villalobos (2016)
Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.ACS chemical neuroscience, 7 6
S. Rizzo, A. Masters, K. Onos, S. Quinney, M. Sasner, A. Oblak, B. Lamb, P. Territo (2020)
Improving preclinical to clinical translation in Alzheimer's disease researchAlzheimer's & Dementia: Translational Research & Clinical Interventions, 6
INTRODUCTIONGiven the mounting human health and economic costs, coupled with the rapidly rising number of Alzheimer's disease (AD) cases worldwide, there is a desperate need to develop therapeutics that can treat, delay, or prevent AD.1 Despite the herculean efforts over the past 20 years to develop disease‐modifying treatments for AD, only two of the more than 400 disease modifying interventions tested to date has gained FDA approval.2 While a wide variety of potential causes of these failures have been proposed2 the lack of translation to the clinic from preclinical efficacy experiments has been thought to contribute significantly.3,4To this end, and to aid in the acceleration of developing treatments for AD, the National Institutes of Aging (NIA) AD Research Summit of 2015 provided a list of recommendations aimed at increasing the predictive value of AD animal models and enabling transparent and reproducible preclinical efficacy testing.5 As a result of these recommendations, the Model Organism Development and Evaluation for Late‐Onset Alzheimer's Disease (MODEL‐AD) consortium was established.6 The overarching aims of this program are to (1) design, develop, and characterize new mouse models for late‐onset AD (LOAD); and (2) establish a preclinical testing core (PTC) that establishes and implements pharmaceutical testing in
Alzheimer s & Dementia – Wiley
Published: Nov 1, 2023
Keywords: Alzheimer's disease; drug development; drug selection; preclinical models
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.